Journal Article

Highly Sensitive Quantitation of Methamphetamine by Time-Resolved Fluoroimmunoassay Using a New Europium Chelate as a Label

Hiroko Kimura, Jingli Yuan, Guilan Wang, Kazuko Matsumoto and Masahiro Mukaida

in Journal of Analytical Toxicology

Volume 23, issue 1, pages 11-16
Published in print January 1999 | ISSN: 0146-4760
Published online January 1999 | e-ISSN: 1945-2403 | DOI: http://dx.doi.org/10.1093/jat/23.1.11
Highly Sensitive Quantitation of Methamphetamine by Time-Resolved Fluoroimmunoassay Using a New Europium Chelate as a Label

More Like This

Show all results sharing these subjects:

  • Medical Toxicology
  • Toxicology (Non-medical)

GO

Show Summary Details

Preview

A simple and highly sensitive time-resolved fluoroimmunoassay of methamphetamine (MA) using a new fluorescent europium chelate (BHHCT-Eu3+) as a label is described. Two variations of competitive immunoassay were attempted. In the first (one-step) assay, microtiter plates coated with anti-MA were used, and the new label was bound to a conjugate of bovine serum albumin and N-(4-aminobutyl)-MA (MA-BSA). In the second (two-step) assay, instead of the labeled MA-BSA, biotinylated MA-BSA and BHHCT-Eu3+-labeled streptavidin-BSA were used. The lowest measurable concentrations of MA for the one-step and the two-step methods were 1 ng/mL (25 pg/assay) and 1 pg/m/(25 fg/assay), respectively. These were 10 to 1000 times superior to the detection limits of MA in any other immunoassay. Intra-assay coefficient of variation was approximately 2–8% at eight different concentrations (n = 4). Analysis of 34 urine samples with the new method and conventional gas chromatography showed a good correlation (r = 0.954). The high detectability of the present assay also enabled segmental hair analysis with a few centimeters of a hair.

Journal Article.  0 words. 

Subjects: Medical Toxicology ; Toxicology (Non-medical)

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.